Smart Ablation Catheter Treats Persistent Atrial Fibrillation
By HospiMedica International staff writers Posted on 27 Oct 2020 |
Image: The Thermocool Smarttouch Catheter (Photo courtesy of Biosense Webster)
An innovative catheter offers a patient-tailored ablation approach that provides long-term efficacy for atrial fibrillation (AF) patients.
The Biosense Webster (Diamond Bar, CA, USA) Thermocool Smarttouch SF Catheter is intended for patients suffering from drug-resistant paroxysmal AF, persistent AF, sustained monomorphic ischemic ventricular tachycardia (VT), and Type I atrial flutter. When coupled together with the proprietary CARTO 3 System, which delivers radio frequency (RF) energy to the device and provides the control interface, physicians can achieve stable, consistent application of contact force by providing direct, real-time quantitative feedback during catheter ablation procedures.
In a study that enrolled 381 patients with documented symptomatic persistent AF who did not respond or were intolerant of antiarrhythmic drug (AAD), a tailored radiofrequency (RF) ablation strategy was used, with pulmonary vein isolation (PVI) and additional left atrial ablations (PVI+) performed at the operator's discretion, based on the patient's disease state. The results showed that 80% of persistent AF patients experienced clinical success at 15 months following ablation therapy, and 86% experienced freedom from repeat procedures.
“Atrial fibrillation is a progressive disease that becomes harder to treat as symptoms become more severe,” said Uri Yaron, worldwide president of Biosense Webster. “We are committed to advancing clinical evidence in partnership with physicians, and this data is encouraging as we continue on our quest to help people live their best lives possible – making sure AF never stands in the way.”
PVI was developed to prevent focal triggers in the pulmonary veins from initiating episodes of AF. The procedure initially involved focal ablation with a catheter directly in the pulmonary veins, but isolating the pulmonary veins by applying ablation energy at their junction with the left atrium was found to be more effective. The PVI procedure is most suitable for patients whose recurring symptomatic episodes of AF that have not been suppressed by AAD, or who do not wish to take long-term anti-arrhythmic or anticoagulation medications.
Related Links:
Biosense Webster
The Biosense Webster (Diamond Bar, CA, USA) Thermocool Smarttouch SF Catheter is intended for patients suffering from drug-resistant paroxysmal AF, persistent AF, sustained monomorphic ischemic ventricular tachycardia (VT), and Type I atrial flutter. When coupled together with the proprietary CARTO 3 System, which delivers radio frequency (RF) energy to the device and provides the control interface, physicians can achieve stable, consistent application of contact force by providing direct, real-time quantitative feedback during catheter ablation procedures.
In a study that enrolled 381 patients with documented symptomatic persistent AF who did not respond or were intolerant of antiarrhythmic drug (AAD), a tailored radiofrequency (RF) ablation strategy was used, with pulmonary vein isolation (PVI) and additional left atrial ablations (PVI+) performed at the operator's discretion, based on the patient's disease state. The results showed that 80% of persistent AF patients experienced clinical success at 15 months following ablation therapy, and 86% experienced freedom from repeat procedures.
“Atrial fibrillation is a progressive disease that becomes harder to treat as symptoms become more severe,” said Uri Yaron, worldwide president of Biosense Webster. “We are committed to advancing clinical evidence in partnership with physicians, and this data is encouraging as we continue on our quest to help people live their best lives possible – making sure AF never stands in the way.”
PVI was developed to prevent focal triggers in the pulmonary veins from initiating episodes of AF. The procedure initially involved focal ablation with a catheter directly in the pulmonary veins, but isolating the pulmonary veins by applying ablation energy at their junction with the left atrium was found to be more effective. The PVI procedure is most suitable for patients whose recurring symptomatic episodes of AF that have not been suppressed by AAD, or who do not wish to take long-term anti-arrhythmic or anticoagulation medications.
Related Links:
Biosense Webster
Latest Surgical Techniques News
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery
- Robotic Nerve ‘Cuffs’ Could Treat Various Neurological Conditions
- Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons
- Next-Gen Computer Assisted Vacuum Thrombectomy Technology Rapidly Removes Blood Clots
- Hydrogel-Based Miniaturized Electric Generators to Power Biomedical Devices
- Custom 3D-Printed Orthopedic Implants Transform Joint Replacement Surgery
- Wearable Technology Monitors and Analyzes Surgeons' Posture during Long Surgical Procedures
- Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery
- Computational Models Predict Heart Valve Leakage in Children
- Breakthrough Device Enables Clear and Real-Time Visual Guidance for Effective Cardiovascular Interventions
- World’s First Microscopic Probe to Revolutionize Early Cancer Diagnosis
- World’s Smallest Implantable Brain Stimulator Demonstrated in Human Patient
- Robotically Assisted Lung Transplants Could Soon Become a Reality
- AI to Provide Heart Transplant Surgeons with New Decision-Making Data
- New Surgical Tool Empowers Precision and Confidence in Operating Room